[go: up one dir, main page]

RU2008139598A - Синбиотическая смесь - Google Patents

Синбиотическая смесь Download PDF

Info

Publication number
RU2008139598A
RU2008139598A RU2008139598/13A RU2008139598A RU2008139598A RU 2008139598 A RU2008139598 A RU 2008139598A RU 2008139598/13 A RU2008139598/13 A RU 2008139598/13A RU 2008139598 A RU2008139598 A RU 2008139598A RU 2008139598 A RU2008139598 A RU 2008139598A
Authority
RU
Russia
Prior art keywords
galβ1
oligosaccharides
drug according
3galβ1
4glc
Prior art date
Application number
RU2008139598/13A
Other languages
English (en)
Other versions
RU2448720C2 (ru
Inventor
Норберт ШПРЕНГЕР (CH)
Норберт ШПРЕНГЕР
Франсуа МОРГАН (FR)
Франсуа Морган
Рафаэль БЕРРОКАЛЬ (CH)
Рафаэль БЕРРОКАЛЬ
Марсель БРАУН (CH)
Марсель БРАУН
Кристин ШЕРБЮ (CH)
Кристин ШЕРБЮ
Питер ДАНКЭН (CH)
Питер ДАНКЭН
Original Assignee
Нестек С.А. (Ch)
Нестек С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нестек С.А. (Ch), Нестек С.А. filed Critical Нестек С.А. (Ch)
Publication of RU2008139598A publication Critical patent/RU2008139598A/ru
Application granted granted Critical
Publication of RU2448720C2 publication Critical patent/RU2448720C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/14—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment
    • A23C9/142—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
    • A23C9/1425—Milk preparations; Milk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration by ultrafiltration, microfiltration or diafiltration of whey, e.g. treatment of the UF permeate
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/519—Breve
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Water Supply & Treatment (AREA)
  • Pediatric Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1. Препарат, содержащий пробиотический бактериальный штамм и пребиотическую смесь, включающую от 5 до 70 мас.% по меньшей мере одного N-ацетилированного олигосахарида, выбранного из группы, состоящей из GalNAcα1,3Galβ1,4Glc и Galβ1, 6GalNAcα1,3Galβ1, 4Glc; от 20 до 95 мас.% по меньшей мере одного нейтрального олигосахарида, выбранного из группы, состоящей из Galβ1,6Gal,Galβ1,6Galβ1,4Glc Galβ1,6Galβ1,6Glc, Galβ1,3Galβ1,3Glc, Galβ1,3Galβ1,4Glc, Galβ1,6Galβ1,6Galβ1,4Glc, Galβ1,6Galβ1,3Galβ1,4Glc Galβ1,3Galβ1,6Galβ1,4Glc и Galβ1,3Galβ1,3Galβ1,4Glc, и от 2 до 50 мас.%, по меньшей мере одного сиалилированного олигосахарида, выбранного из группы, состоящей из NeuAcα2,3Galβ1,4Glc и NeuAcα2,6Galβ1,4Glc. ! 2. Препарат по п.1, в котором пребиотическая смесь включает от 15 до 40 мас.% N-ацетилированных олигосахаридов, от 40 до 60 мас.% нейтральных олигосахаридов и от 15 до 30 мас.% сиалилированных олигосахаридов. ! 3. Препарат по п.1 или 2, в котором смесь олигосахаридов включает 30 мас.% N-ацетилированных олигосахаридов, 50 мас.% нейтральных олигосахаридов и 20 мас.% сиалилированных олигосахаридов. ! 4. Препарат по п.1, в котором смесь олигосахаридов включает от 5 до 20 мас.% N-ацетилированных олигосахаридов, от 60 до 95 мас.% нейтральных олигосахаридов и от 2 до 30 мас.% сиалилированных олигосахаридов. ! 5. Препарат по п.1, в котором пробитический бактериальный штамм является штаммом Lactobacillus. ! 6. Препарат по п.6, в котором штамм Lactobacillus представлен Lactobacillus rhamnosus, Lactobacillus paracasei или Lactobacillus reuteri. ! 7. Препарат по п.6, в котором штамм Lactobacillus представлен Lactobacillus rhamnosus CGMCC 1.3724. ! 8. Препарат по п.6, в котором штамм Lactobacillus представлен Lactobacillus paracasei CNCM I-2116. ! 9. Препарат по п.1, в котором пробиотический бактериальный штамм представлен штаммом Bifidobacterium. ! 10. Препарат по п.9, в котором штамм Bifidobacterium пр

Claims (19)

1. Препарат, содержащий пробиотический бактериальный штамм и пребиотическую смесь, включающую от 5 до 70 мас.% по меньшей мере одного N-ацетилированного олигосахарида, выбранного из группы, состоящей из GalNAcα1,3Galβ1,4Glc и Galβ1, 6GalNAcα1,3Galβ1, 4Glc; от 20 до 95 мас.% по меньшей мере одного нейтрального олигосахарида, выбранного из группы, состоящей из Galβ1,6Gal,Galβ1,6Galβ1,4Glc Galβ1,6Galβ1,6Glc, Galβ1,3Galβ1,3Glc, Galβ1,3Galβ1,4Glc, Galβ1,6Galβ1,6Galβ1,4Glc, Galβ1,6Galβ1,3Galβ1,4Glc Galβ1,3Galβ1,6Galβ1,4Glc и Galβ1,3Galβ1,3Galβ1,4Glc, и от 2 до 50 мас.%, по меньшей мере одного сиалилированного олигосахарида, выбранного из группы, состоящей из NeuAcα2,3Galβ1,4Glc и NeuAcα2,6Galβ1,4Glc.
2. Препарат по п.1, в котором пребиотическая смесь включает от 15 до 40 мас.% N-ацетилированных олигосахаридов, от 40 до 60 мас.% нейтральных олигосахаридов и от 15 до 30 мас.% сиалилированных олигосахаридов.
3. Препарат по п.1 или 2, в котором смесь олигосахаридов включает 30 мас.% N-ацетилированных олигосахаридов, 50 мас.% нейтральных олигосахаридов и 20 мас.% сиалилированных олигосахаридов.
4. Препарат по п.1, в котором смесь олигосахаридов включает от 5 до 20 мас.% N-ацетилированных олигосахаридов, от 60 до 95 мас.% нейтральных олигосахаридов и от 2 до 30 мас.% сиалилированных олигосахаридов.
5. Препарат по п.1, в котором пробитический бактериальный штамм является штаммом Lactobacillus.
6. Препарат по п.6, в котором штамм Lactobacillus представлен Lactobacillus rhamnosus, Lactobacillus paracasei или Lactobacillus reuteri.
7. Препарат по п.6, в котором штамм Lactobacillus представлен Lactobacillus rhamnosus CGMCC 1.3724.
8. Препарат по п.6, в котором штамм Lactobacillus представлен Lactobacillus paracasei CNCM I-2116.
9. Препарат по п.1, в котором пробиотический бактериальный штамм представлен штаммом Bifidobacterium.
10. Препарат по п.9, в котором штамм Bifidobacterium представлен Bifidobacterium lactis, Bifidobacterium longum и Bifidobacterium breve.
11. Препарат по п.9, в котором штамм Bifidobacterium представлен Bifidobacterium longum ATCC ВАА-999.
12. Пищевой продукт, содержащий препарат по любому из пп.1-11.
13. Пищевой продукт по п.12, который является смесью для детского питания.
14. Пищевой продукт по п.12 или 13, который содержит от 0,3 до 4 мас.% (в пересчете на сухое вещество) препарата по любому из предшествующих пп.1-11.
15. Применение препарата по любому из пп.1-11 в производстве лечебной питательной композиции или лекарственного средства для предупреждения или лечения патогенных инфекций желудочно-кишечного тракта.
16. Применение по п.15, в котором инфекция вызвана патогенными бактериями.
17. Применение препарата по любому из пп.1-11 в производстве лечебной питательной композиции или лекарственного средства для предупреждения или лечения иммунного состояния.
18. Применение препарата по любому из пп.1-11 в производстве лечебной питательной композиции или лекарственного средства для предупреждения или лечения инфекций верхних дыхательных путей.
19. Применение препарата по любому из пп.1-11 в производстве лечебной питательной композиции или лекарственного средства для приживления бифидогенной кишечной микробиоты и/или для повышения метаболической активности такой бифидогенной кишечной микробиоты.
RU2008139598/15A 2006-03-07 2007-03-07 Синбиотическая смесь RU2448720C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06110805 2006-03-07
EP06110805.6 2006-03-07

Publications (2)

Publication Number Publication Date
RU2008139598A true RU2008139598A (ru) 2010-04-20
RU2448720C2 RU2448720C2 (ru) 2012-04-27

Family

ID=37054559

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008139598/15A RU2448720C2 (ru) 2006-03-07 2007-03-07 Синбиотическая смесь

Country Status (14)

Country Link
US (2) US9005682B2 (ru)
EP (1) EP1993576B1 (ru)
CN (1) CN101432007A (ru)
AU (1) AU2007222598B2 (ru)
BR (1) BRPI0708689A2 (ru)
CA (1) CA2644968A1 (ru)
ES (1) ES2553636T3 (ru)
MX (1) MX2008011450A (ru)
MY (1) MY149913A (ru)
PL (1) PL1993576T3 (ru)
PT (1) PT1993576E (ru)
RU (1) RU2448720C2 (ru)
WO (1) WO2007101675A1 (ru)
ZA (1) ZA200808503B (ru)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
FR2895877B1 (fr) * 2006-01-06 2012-06-22 Gervais Danone Sa Poudre de lait fermente ou yaourt a haute densite en ferments lactiques
WO2007090894A1 (en) † 2006-02-10 2007-08-16 Nestec S.A. Oligosaccharide mixture
EP1974734A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics for reduction of risk of obesity
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
EP2060257A1 (en) * 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
EP2265135B1 (en) 2008-03-14 2017-12-20 Nestec S.A. Synbiotic mixture
CN102065872A (zh) * 2008-05-27 2011-05-18 雀巢产品技术援助有限公司 改善肠微生物群的益生菌
EP2127661A1 (en) * 2008-05-27 2009-12-02 Nestec S.A. Probiotics to improve gut microbiotica
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
EP2147678A1 (en) * 2008-07-21 2010-01-27 Nestec S.A. Probiotics to increase IgA secretion in infants born by caesarean section
PL2172117T3 (pl) 2008-09-25 2012-04-30 Nestec Sa Zmniejszenie cierpkości w kompozycjach zawierających fenolowe związki
MY177636A (en) * 2008-11-28 2020-09-23 Univ Of Otago Use of lactic acid bacteria to treat or prevent eczema
CA2746805A1 (en) * 2008-12-19 2010-06-24 Nestec S.A. Prevention and treatment of rotavirus diarrhoea
ES2600960T3 (es) 2009-02-24 2017-02-13 Ritter Pharmaceuticals, Inc. Formulaciones prebióticas y procedimientos de uso
PT2429539T (pt) * 2009-05-11 2017-01-12 Nestec Sa Lactobacilos johnsonii la1 ncc533 não replicativo (cncm i-1225) e distúrbios imunitários
WO2010143940A1 (en) * 2009-06-12 2010-12-16 N.V. Nutricia Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages
EP2289527B1 (en) 2009-08-25 2018-02-21 Nestec S.A. Bifidobacterium longum and functional GI disorders
EA200901521A1 (ru) * 2009-11-10 2010-04-30 Лев Михайлович МОГИЛЕВСКИЙ Сухая молочная смесь и упаковка для нее
RU2009141298A (ru) * 2009-11-10 2011-05-20 Лев Михайлович Могилевский (RU) Сухая молочная смесь и упаковка для нее
WO2011090926A1 (en) 2010-01-19 2011-07-28 Abbott Laboratories Nutritional formulas containing synbiotics
NL2004200C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides in weight management.
NL2004201C2 (en) 2010-02-05 2011-08-08 Friesland Brands Bv Use of sialyl oligosaccharides to modulate the immune system.
WO2011137249A1 (en) * 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
US9200091B2 (en) * 2010-07-12 2015-12-01 The Regents Of The University Of California Bovine milk oligosaccharides
EP2452571A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of complementary infant/young child nutritional compositions
EP2454948A1 (en) 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
EP2455387A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
MX336031B (es) 2010-12-21 2016-01-07 Nestec Sa Recipiente y bolsa.
SG191797A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods of using human milk oligosaccharides for improving airway respiratory health
MX376863B (es) 2010-12-31 2025-03-07 Abbott Lab Metodos para disminuir la incidencia de la enterocolitis necrotizante en bebes, infantes, o niños al usar los oligosacaridos de leche humana.
MY191538A (en) 2010-12-31 2022-06-30 Abbott Lab Human milk oligosaccharides to promote growth of beneficial bacteria
DK2658548T3 (en) 2010-12-31 2018-05-07 Abbott Lab OLIGOSACCHARIDES OF MOTHER MILK FOR MODULATING INFLAMMATION
PH12013501358A1 (en) 2010-12-31 2013-08-28 Abbott Lab Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
CN103379908B (zh) 2010-12-31 2020-02-14 雅培制药有限公司 使用人乳寡糖、维生素c和抗炎剂减少氧化应激的发病率的方法
EP2658402A1 (en) * 2010-12-31 2013-11-06 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
SG191799A1 (en) 2010-12-31 2013-08-30 Abbott Lab Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof
DK2672980T3 (en) * 2011-02-09 2018-02-26 Lavivo Ab SYNBIOTIC COMPOSITIONS FOR GETTING UP AND RECONSTITUTING GAS MICROFLORA
US20120263696A1 (en) * 2011-04-14 2012-10-18 Stefan Roos Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol
ITMI20110792A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) * 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
EP2526784A1 (en) * 2011-05-24 2012-11-28 Nestec S.A. Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
US9125935B1 (en) 2011-05-31 2015-09-08 Nutech Ventures Probiotics and methods of obtaining same
MY187589A (en) 2011-06-20 2021-09-30 Heinz Co Brands H J Llc Probiotic compositions and methods
MX2014000458A (es) * 2011-07-12 2014-05-01 Nestec Sa Probioticos para la administracion a mamiferos jovenes saludables durante el periodo de destete para mejorar l atolerancia a productos alimenticios de introduccion reciente.
US11446316B2 (en) 2011-07-22 2022-09-20 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MX368124B (es) 2011-08-29 2019-09-19 Abbott Lab Oligosacaridos de leche humana para prevenir lesion y/o promover cicatrizacion del tracto gastrointestinal.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
BR112014008944B1 (pt) 2011-10-18 2020-09-15 Société des Produits Nestlé S.A. Composição nutricional simbiótica compreendendo lc-pufa, probiótico e mistura de oligossacarídeos para crescimento cerebral e/ou desenvolvimento cognitivo e/ou psicomotor
ES2546262T5 (es) 2011-10-18 2019-04-12 Nestec Sa Composición para emplear en la promoción de la absorción del magnesio y/o la retención del magnesio
AU2012324985B2 (en) * 2011-10-18 2016-01-07 Société des Produits Nestlé S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
PH12014500453A1 (en) * 2011-10-18 2020-12-18 Socia‰Ta‰ Des Produits Nestla‰ S A Composition for use in increasing insulin sensitivity and/or reducing insulin resistance
BR112014009097A2 (pt) 2011-10-18 2017-04-18 Nestec Sa composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
WO2015071389A1 (en) * 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
WO2015091789A2 (en) 2013-12-19 2015-06-25 Nestec S.A. Nutritional composition to reduce metabolic stress in infants
EP3536168A3 (en) 2014-03-06 2019-10-16 The Research Institute at Nationwide Children's Hospital Probiotic formulations and methods for use
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
EP3510876A1 (en) * 2015-01-26 2019-07-17 Stephanie Lynch Broth compositions and their use as prebiotics
MA45334A (fr) 2016-03-24 2019-01-30 Probiotical Spa Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes
ES2992190T3 (es) * 2016-08-04 2024-12-10 Nestle Sa Composiciones nutritivas y fórmulas infantiles que comprenden una mezcla de oligosacáridos y, opcionalmente, Bifidobacterium lactis para prevenir, tratar o reducir la gravedad de la diarrea asociada a no rotavirus
CN106617091A (zh) * 2016-11-08 2017-05-10 广东正当年生物科技有限公司 一种益生菌和益生元复合制剂
MY206997A (en) * 2017-12-21 2025-01-23 Nestle Sa Compositions for use in the promotion of intestinal muscle growth and development and associated intestinal motility
WO2020141032A1 (en) * 2019-01-02 2020-07-09 Frieslandcampina Nederland B.V. Method for preparing gos-preparation with beta-galactosidase from cryptococcus terrestris, gos preparations obtainable thereby and uses thereof
KR20220016481A (ko) 2019-06-03 2022-02-09 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 패혈증 및 괴사성 장염 유도된 신경발달 결핍의 예방을 위한 프리바이오틱 제형
JP7493713B2 (ja) * 2019-10-31 2024-06-03 国立大学法人東京工業大学 浮遊培養用培地添加剤、培地組成物及び培養方法
GB2619977A (en) * 2022-06-24 2023-12-27 Clasado Res Services Limited Compositions and uses thereof
WO2025224241A1 (en) * 2024-04-25 2025-10-30 Frieslandcampina Nederland B.V. Galacto-oligosaccharide preparation enriched in sialyllactose
WO2025224242A1 (en) * 2024-04-25 2025-10-30 Frieslandcampina Nederland B.V. Galacto-oligosaccharide preparation enriched in sialyllactose

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
ATE161181T1 (de) 1992-07-06 1998-01-15 Nestle Sa Lactobacillus acidophilus enthaltende antigastritis-mittel
ATE153063T1 (de) * 1992-07-06 1997-05-15 Nestle Sa Milchbakterien
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
EP0856259B1 (en) 1996-12-23 1998-08-12 SITIA-YOMO S.p.A. Composition for feed use comprising lyophilized live lactic bacteria
EP0904784A1 (en) 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
DE19958985A1 (de) 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharidmischung
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
FI109602B (fi) 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
EP1243273A1 (en) 2001-03-22 2002-09-25 Societe Des Produits Nestle S.A. Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20040072794A1 (en) * 2002-10-11 2004-04-15 Wyeth Nutritional formulations containing synbiotic substances
FI20021989A0 (fi) 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
JP2007506536A (ja) 2003-06-27 2007-03-22 バイオ−サーキット エーピーエス 嫌気性加水分解によるバイオガス生産設備
PT1675481E (pt) * 2003-10-24 2009-01-02 Nutricia Nv Composição sinbiótica para bebés
EP1629850B2 (en) 2004-08-24 2013-05-22 N.V. Nutricia Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides
CA2532062A1 (fr) 2005-01-14 2006-07-14 Nutrinor Cooperative Agro-Alimentaire Du Saguenay Lac St-Jean Composition alimentaire pour maintien et retablissement des fonctions digestives
US8591981B2 (en) 2005-02-21 2013-11-26 Nestec S.A. Oligosaccharide mixture
CA2500724A1 (fr) * 2005-03-16 2005-06-20 Nutrinor Cooperative Agro-Alimentaire Du Saguenay Lac St-Jean Composition alimentaire pour maintien et retablissement des fonctions digestives
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota

Also Published As

Publication number Publication date
CA2644968A1 (en) 2007-09-13
PT1993576E (pt) 2016-01-25
ES2553636T3 (es) 2015-12-10
PL1993576T3 (pl) 2016-04-29
AU2007222598A1 (en) 2007-09-13
ZA200808503B (en) 2009-12-30
MX2008011450A (es) 2008-09-24
EP1993576B1 (en) 2015-10-21
US9005682B2 (en) 2015-04-14
AU2007222598B2 (en) 2013-01-10
RU2448720C2 (ru) 2012-04-27
MY149913A (en) 2013-10-31
CN101432007A (zh) 2009-05-13
US20150174179A1 (en) 2015-06-25
WO2007101675A1 (en) 2007-09-13
BRPI0708689A2 (pt) 2011-06-07
US20090041736A1 (en) 2009-02-12
US10092606B2 (en) 2018-10-09
EP1993576A1 (en) 2008-11-26

Similar Documents

Publication Publication Date Title
RU2008139598A (ru) Синбиотическая смесь
RU2009139660A (ru) Пробиотики для сокращения числа случаев диареи у детей, рожденных путем кесарева сечения
RU2010153257A (ru) Пробиотики для улудшения микробиоты пищеварительного тракта
RU2011106319A (ru) Пробиотики для увелечения секреции iga у младенцев, рожденных посредством кесарева сечения
RU2011104195A (ru) Питательная композиция, содержащая смесь олигосахаридов
JP6444358B2 (ja) ペディオコッカスを含有する医薬組成物および消化器症候群の症状を低減する方法
Gupta et al. Probiotics
RU2010142003A (ru) Синбиотическая смесь
RU2012140052A (ru) Композиция, содержащая пробиотические бактерии, для применения в лечении иммунных расстройств
RU2009139665A (ru) Пробиотики для снижения риска ожирения
RU2011110056A (ru) Пищевая композиция с пробиотиками
EP2308499A1 (en) Bifidobacterium longum ATCC BAA-999 (BL999) and weight control
RU2014119844A (ru) Композиция для головного мозга и/или познавательного и/или психомоторного развития
RU2011139211A (ru) Бактериальные штаммы, обладающие высокой противовоспалительной активностью
RU2016129426A (ru) Питательная композиция для снижения метаболического стресса у младенцев
EP2465509A1 (en) Oligosaccharide composition for treating acute respiratory tract infections
RU2009139657A (ru) Снижение риска диареи
Ogueke et al. Probiotics and prebiotics: Unfolding prospects for better human health
AU2010213010B2 (en) Lactobacillus rhamnosus CNCM I-4096 and weight control
CN106659226A (zh) 用于降低以后生命中肥胖风险的益生元
AU2019407214B2 (en) A nutritional composition comprising metabolites of HMOs to improve the gastrointestinal barrier
Thomsen Probiotics–enhancing health with beneficial bacteria
RU2830241C2 (ru) Питательная композиция, содержащая метаболиты огм, для улучшения желудочно-кишечного барьера
Mikelsaar et al. Teaduspõhiselt probiootikumidest: kas innovatiivsus on jõudnud probiootikumide rakendamiseni?
Upadhyay et al. Clinical Benefits of Manipulating the Gut Flora

Legal Events

Date Code Title Description
QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20101006

Effective date: 20150710

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: LICENCE FORMERLY AGREED ON 20101006

Effective date: 20170316

PC43 Official registration of the transfer of the exclusive right without contract for inventions

Effective date: 20190916